Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
24-26 February, 2026
BIO Partnering at JPMBIO Partnering at JPM
Not Confirmed
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Not Confirmed
Not Confirmed
12-14 January, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Tides Asia
Not Confirmed
Contact SupplierTides Asia
Industry Trade Show
Not Confirmed
24-26 February, 2026
BIO Partnering at JPMBIO Partnering at JPM
Industry Trade Show
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Industry Trade Show
Not Confirmed
12-14 January, 2026
Digital content
NEWS #PharmaBuzz
01 Apr 2022
// J. Sullivan ENDPTS
https://endpts.com/agc-to-use-recently-expanded-germany-site-for-peanut-allergy-drug-trials/
31 Mar 2022
// PRESS RELEASE
https://www.agcbio.com/news/allergy-therapeutics-selects-agc-biologics-to-manufacture-novel-peanut-allergy-vaccine-candidate
26 Jan 2022
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2022/01/26/2373343/0/en/Allergy-Therapeutics-announces-FDA-clearance-of-IND-application-for-novel-peanut-allergy-vaccine-candidate-VLP-Peanut.html
13 Sep 2021
// INVESTEGATE
https://www.investegate.co.uk/allergy-therapeutics--agy-/rns/secondary-endpoints-from-vlp-peanut-001/202109130700074838L/
03 Aug 2021
// INVESTEGATE
https://www.investegate.co.uk/allergy-therapeutics--agy-/rns/successful-primary-outcome-of-vlp-peanut-001/202108030700073254H/
06 May 2021
// DIRECTORSTALKINTERVIEWS
https://www.directorstalkinterviews.com/allergy-therapeutics-announces-completion-of-treatment-phase-in-innovative-g309-exploratory-field-study/412985692
Drugs in Development
Details:
PQGrass306 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Rhinitis, Allergic, Seasonal.
Lead Product(s): PQGrass306
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 15, 2022
Lead Product(s) : PQGrass306
Therapeutic Area : Immunology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PQGrass306 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Rhinitis, Allergic, Seasonal.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 15, 2022
Details:
VLP Peanut is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Peanut Hypersensitivity.
Lead Product(s): VLP Peanut
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Vaccine
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 27, 2022
Lead Product(s) : VLP Peanut
Therapeutic Area : Immunology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects
Details : VLP Peanut is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Peanut Hypersensitivity.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
July 27, 2022
Details:
HoloBLG is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Hypersensitivity.
Lead Product(s): holoBLG
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Dietary Supplement
Sponsor: Ecarf Institute GmbH | Bencard Allergie GmbH
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 13, 2022
Lead Product(s) : holoBLG
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Ecarf Institute GmbH | Bencard Allergie GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of holoBLG on Cat Allergic Patients
Details : HoloBLG is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Hypersensitivity.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
July 13, 2022
Details:
Under the terms of the agreement, AGC Biologics is supporting the manufacturing and testing of Allergy Therapeutics’ VLP Peanut vaccine candidate, providing VLP material for Phase I supply.
Lead Product(s): VLP Peanut
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: IND EnablingProduct Type: Vaccine
Sponsor: AGC Biologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 31, 2022
Lead Product(s) : VLP Peanut
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : AGC Biologics
Deal Size : Undisclosed
Deal Type : Partnership
Allergy Therapeutics Selects AGC Biologics to Manufacture Novel Peanut Allergy Vaccine Candidate
Details : Under the terms of the agreement, AGC Biologics is supporting the manufacturing and testing of Allergy Therapeutics’ VLP Peanut vaccine candidate, providing VLP material for Phase I supply.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
March 31, 2022
Details:
Under the terms of the agreement, AGC Biologics is supporting the manufacturing and testing of Allergy Therapeutics’ VLP Peanut vaccine candidate, providing VLP material for Phase I supply.
Lead Product(s): VLP-based Peanut Allergy Vaccine
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: IND EnablingProduct Type: Vaccine
Recipient: AGC Biologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 31, 2022
Lead Product(s) : VLP-based Peanut Allergy Vaccine
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Recipient : AGC Biologics
Deal Size : Undisclosed
Deal Type : Partnership
Allergy Therapeutics Selects AGC Biologics to Manufacture Peanut Allergy Vaccine Candidate
Details : Under the terms of the agreement, AGC Biologics is supporting the manufacturing and testing of Allergy Therapeutics’ VLP Peanut vaccine candidate, providing VLP material for Phase I supply.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
March 31, 2022
Details:
PQGrass309 is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Rhinitis, Allergic, Seasonal.
Lead Product(s): PQGrass309
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase II/ Phase IIIProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 29, 2020
Lead Product(s) : PQGrass309
Therapeutic Area : Immunology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
An Exploratory Study of PQ Grass 27600 SU
Details : PQGrass309 is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Rhinitis, Allergic, Seasonal.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 29, 2020
Details:
Allergy Therapeutics announces start of key exploratory field study in advance of pivotal Phase III Grass trial;Breakthrough study design to deliver for the first time cutting edge scientific concepts in the Allergy field to optimize SCIT trial results.
Lead Product(s): Grass MATA MPL
Therapeutic Area: Immunology Brand Name: Grass MATA MPL
Study Phase: Phase IIIProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 26, 2020
Lead Product(s) : Grass MATA MPL
Therapeutic Area : Immunology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Allergy Therapeutics announces start of key exploratory field study in advance of pivotal Phase III Grass trial;Breakthrough study design to deliver for the first time cutting edge scientific concepts in the Allergy field to optimize SCIT trial results.
Product Name : Grass MATA MPL
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 26, 2020
Details:
Technical issues in the study made it difficult to reconstruct the primary endpoint data and the PEI agreed that B301 cannot be considered for assessment of clinical efficacy and a new pivotal Phase III study will be conducted within the therapy allergens ordinance time frame.
Lead Product(s): Tree MATA MPL
Therapeutic Area: Immunology Brand Name: Tree MATA MPL
Study Phase: Phase IIIProduct Type: Vaccine
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 09, 2020
Lead Product(s) : Tree MATA MPL
Therapeutic Area : Immunology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Technical issues in the study made it difficult to reconstruct the primary endpoint data and the PEI agreed that B301 cannot be considered for assessment of clinical efficacy and a new pivotal Phase III study will be conducted within the therapy allergen...
Product Name : Tree MATA MPL
Product Type : Vaccine
Upfront Cash : Inapplicable
July 09, 2020
Details:
Grass MATA MPL is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Rhinitis, Allergic, Seasonal.
Lead Product(s): Grass MATA MPL
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Undisclosed
Sponsor: Syneos Health | Metronomia Clinical Research
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 30, 2019
Lead Product(s) : Grass MATA MPL
Therapeutic Area : Immunology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Syneos Health | Metronomia Clinical Research
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Tolerability and Safety of a New Cumulative Dose of Grass MATA MPL
Details : Grass MATA MPL is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Rhinitis, Allergic, Seasonal.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 30, 2019
Details:
Grass MATA MPL Extract is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Rhinitis, Allergic, Seasonal.
Lead Product(s): Grass MATA MPL Extract
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Plant Extract/Herbal
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 21, 2015
Lead Product(s) : Grass MATA MPL Extract
Therapeutic Area : Immunology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Grass MATA MPL Extract is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Rhinitis, Allergic, Seasonal.
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
October 21, 2015
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
Share 
